Abstract
The growing demands for existing biologics production are reflected in
biopharmaceutical sales figures: The top 15 products in 2004 posted revenues
of $38 billion. Although biologics manufacturing now is focused chiefly on a
small number of blockbuster products, the future challenges will involve the
ability to gear up for the production of a larger variety of products with
lower sales volumes. D&MD's Bioprocesses of Biopharmaceuticals: The Obligatory
Role of Post Translational Modifications to Create Functional Bioactive
Molecules looks at protein drug manufacturing, starting with choice of methods
and scale-up processes, highlighting important post translational
modifications such as glycosylation.
View Cart
